Log in | Register

Understanding cytokine release syndrome

Philipp Gödel| Alexander Shimabukuro-Vornhagen| Michael von Bergwelt-Baildon
Understanding the Disease
Volume 44, Issue 3 / March , 2018

Pages 371 - 373

No abstract available.

References

  1. Winkler U, Jensen M, Manzke O et al (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94:2217–2224
    • View reference on PubMed
  2. Alig SK, Dreyling M, Seppi B et al (2015) Severe cytokine release syndrome after the first dose of brentuximab vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature. Eur J Haematol 94:554–557. doi:10.1111/ejh.12396
    • View reference on publisher's website
    • View reference on PubMed
  3. Xu X-J, Tang Y-M (2014) Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett 343:172–178. doi:10.1016/j.canlet.2013.10.004
    • View reference on publisher's website
    • View reference on PubMed
  4. Teachey DT, Rheingold SR, Maude SL et al (2013) Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121:5154–5157
    • View reference on publisher's website
    • View reference on PubMed
  5. Park JH, Geyer MB, Brentjens RJ (2016) CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 127:3312–3320
    • View reference on publisher's website
    • View reference on PubMed
  6. Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188–195. doi:10.1182/blood-2014-05-552729
    • View reference on publisher's website
    • View reference on PubMed
  7. Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127:3321–3330
    • View reference on publisher's website
    • View reference on PubMed
  8. Shimabukuro-Vornhagen A, Böll B, Kochanek M et al (2016) Critical care of patients with cancer. CA Cancer J Clin 66:496–517. doi:10.3322/caac.21351
    • View reference on publisher's website
  9. Fitzgerald JC, Weiss SL, Maude SL et al (2017) Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med 45:e124–e131. doi:10.1097/CCM.0000000000002053
    • View reference on publisher's website
    • View reference on PubMed
  10. Davila ML, Riviere I, Wang X et al (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra25. doi:10.1126/scitranslmed.3008226
    • View reference on publisher's website
    • View reference on PubMed
  11. Tanaka T, Narazaki M, Kishimoto T (2016) Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 8:959–970. doi:10.2217/imt-2016-0020
    • View reference on publisher's website
    • View reference on PubMed
  12. Teachey DT, Lacey SF, Shaw PA et al (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6:664–679. doi:10.1158/2159-8290.CD-16-0040
    • View reference on publisher's website
    • View reference on PubMed
  13. Turtle CJ, Hanafi L-A, Berger C et al (2016) CD19 CAR–T cells of defined CD4+: CD8+ composition in adult B cell ALL patients. J Clin Invest 126:2123–2138. doi:10.1172/JCI85309
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement